bioprobe limited
bioprobe limited Company Information
Company Number
08871624
Website
bioprobedx.comRegistered Address
41b beach road, littlehampton, west sussex, BN17 5JA
Industry
Research and experimental development on biotechnology
Telephone
-
Next Accounts Due
October 2024
Group Structure
View All
Directors
Gregory Mullen10 Years
Shareholders
bionext systems pte ltd 60%
mullbiologics consultancy ltd 40%
bioprobe limited Estimated Valuation
Pomanda estimates the enterprise value of BIOPROBE LIMITED at £105.7k based on a Turnover of £105.6k and 1x industry multiple (adjusted for size and gross margin).
bioprobe limited Estimated Valuation
Pomanda estimates the enterprise value of BIOPROBE LIMITED at £0 based on an EBITDA of £-778 and a 4.02x industry multiple (adjusted for size and gross margin).
bioprobe limited Estimated Valuation
Pomanda estimates the enterprise value of BIOPROBE LIMITED at £107.9k based on Net Assets of £47.2k and 2.29x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Bioprobe Limited Overview
Bioprobe Limited is a live company located in west sussex, BN17 5JA with a Companies House number of 08871624. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in January 2014, it's largest shareholder is bionext systems pte ltd with a 60% stake. Bioprobe Limited is a established, micro sized company, Pomanda has estimated its turnover at £105.6k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Bioprobe Limited Health Check
Pomanda's financial health check has awarded Bioprobe Limited a 1.5 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 8 areas for improvement. Company Health Check FAQs
1 Strong
1 Regular
8 Weak
Size
annual sales of £105.6k, make it smaller than the average company (£3.3m)
- Bioprobe Limited
£3.3m - Industry AVG
Growth
3 year (CAGR) sales growth of -7%, show it is growing at a slower rate (13.2%)
- Bioprobe Limited
13.2% - Industry AVG
Production
with a gross margin of 28.3%, this company has a higher cost of product (53.7%)
- Bioprobe Limited
53.7% - Industry AVG
Profitability
an operating margin of -0.7% make it less profitable than the average company (-0.2%)
- Bioprobe Limited
-0.2% - Industry AVG
Employees
with 1 employees, this is below the industry average (42)
- Bioprobe Limited
42 - Industry AVG
Pay Structure
on an average salary of £74.5k, the company has an equivalent pay structure (£74.5k)
- Bioprobe Limited
£74.5k - Industry AVG
Efficiency
resulting in sales per employee of £105.6k, this is less efficient (£131.7k)
- Bioprobe Limited
£131.7k - Industry AVG
Debtor Days
it gets paid by customers after 162 days, this is later than average (53 days)
- Bioprobe Limited
53 days - Industry AVG
Creditor Days
its suppliers are paid after 0 days, this is quicker than average (67 days)
- Bioprobe Limited
67 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Bioprobe Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Bioprobe Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 0.4%, this is a lower level of debt than the average (50%)
0.4% - Bioprobe Limited
50% - Industry AVG
BIOPROBE LIMITED financials
Bioprobe Limited's latest turnover from January 2023 is estimated at £105.6 thousand and the company has net assets of £47.2 thousand. According to their latest financial statements, we estimate that Bioprobe Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||
| Other Income Or Grants | |||||||||
| Cost Of Sales | |||||||||
| Gross Profit | |||||||||
| Admin Expenses | |||||||||
| Operating Profit | |||||||||
| Interest Payable | |||||||||
| Interest Receivable | |||||||||
| Pre-Tax Profit | |||||||||
| Tax | |||||||||
| Profit After Tax | |||||||||
| Dividends Paid | |||||||||
| Retained Profit | |||||||||
| Employee Costs | |||||||||
| Number Of Employees | 1 | 1 | 1 | 1 | |||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 499 | 665 | 888 | 1,183 | 1,578 | 2,104 | 2,805 | 946 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 499 | 665 | 888 | 1,183 | 1,578 | 2,104 | 2,805 | 946 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 46,882 | 47,510 | 48,549 | 50,475 | 69,934 | 77,600 | 65,248 | 45,928 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11,326 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 46,882 | 47,510 | 48,549 | 50,475 | 69,934 | 77,600 | 65,248 | 57,254 | 0 |
| total assets | 47,381 | 48,175 | 49,437 | 51,658 | 71,512 | 79,704 | 68,053 | 58,200 | 0 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 172 | 188 | 492 | 1,227 | 17,291 | 48,161 | 30,325 | 67,951 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 172 | 188 | 492 | 1,227 | 17,291 | 48,161 | 30,325 | 67,951 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 172 | 188 | 492 | 1,227 | 17,291 | 48,161 | 30,325 | 67,951 | 0 |
| net assets | 47,209 | 47,987 | 48,945 | 50,431 | 54,221 | 31,543 | 37,728 | -9,751 | 0 |
| total shareholders funds | 47,209 | 47,987 | 48,945 | 50,431 | 54,221 | 31,543 | 37,728 | -9,751 | 0 |
| Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Operating Profit | |||||||||
| Depreciation | 315 | ||||||||
| Amortisation | 0 | ||||||||
| Tax | |||||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -628 | -1,039 | -1,926 | -19,459 | -7,666 | 12,352 | 19,320 | 45,928 | 0 |
| Creditors | -16 | -304 | -735 | -16,064 | -30,870 | 17,836 | -37,626 | 67,951 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | |||||||||
| Investing Activities | |||||||||
| capital expenditure | |||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||
| Financing Activities | |||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||
| interest | |||||||||
| cash flow from financing | |||||||||
| cash and cash equivalents | |||||||||
| cash | 0 | 0 | 0 | 0 | 0 | 0 | -11,326 | 11,326 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | 0 | -11,326 | 11,326 | 0 |
bioprobe limited Credit Report and Business Information
Bioprobe Limited Competitor Analysis
Perform a competitor analysis for bioprobe limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in BN17 area or any other competitors across 12 key performance metrics.
bioprobe limited Ownership
BIOPROBE LIMITED group structure
Bioprobe Limited has no subsidiary companies.
Ultimate parent company
BIOPROBE LIMITED
08871624
bioprobe limited directors
Bioprobe Limited currently has 1 director, Mr Gregory Mullen serving since Jan 2014.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Gregory Mullen | France | 52 years | Jan 2014 | - | Director |
P&L
January 2023turnover
105.6k
+26%
operating profit
-778
0%
gross margin
28.3%
+1.17%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
January 2023net assets
47.2k
-0.02%
total assets
47.4k
-0.02%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
bioprobe limited company details
company number
08871624
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
January 2014
age
10
incorporated
UK
accounts
Micro-Entity Accounts
ultimate parent company
previous names
N/A
last accounts submitted
January 2023
address
41b beach road, littlehampton, west sussex, BN17 5JA
accountant
-
auditor
-
bioprobe limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to bioprobe limited.
bioprobe limited Companies House Filings - See Documents
| date | description | view/download |
|---|
